Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07456696 · ClinicalTrials.gov registry record · Phase 3

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

A Phase 3 study of Post Traumatic Stress Disorder, sponsored by Transcend Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
300
Enrollment target
3
Study locations

NCT07456696 is a Phase 3 study of Post Traumatic Stress Disorder that is actively recruiting participants, run by Transcend Therapeutics. The registered enrollment target is 300 participants, below the 1,115-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07456696, a Phase 3 study of Post Traumatic Stress Disorder, is actively recruiting participants, sponsored by Transcend Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
300 participants
Enrollment target
3
Study locations

Study Summary

This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.

Interventions

  • DRUG Placebo
  • DRUG TSND-201

Study Locations (3)

Florida

  • CNS Healthcare - Jacksonville
  • CNS Healthcare - Orlando

Arkansas

  • Preferred Research Partners - Little Rock

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2026-03
Est. Completion 2027-12
Phase Phase 3

Sponsor

Transcend Therapeutics

4 total trials

What the Registry Record Tells You About NCT07456696

The ClinicalTrials.gov registry entry for NCT07456696 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,115-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (73% lower). The listed sponsor is Transcend Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07456696 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Arkansas.

Frequently Asked Questions

What is clinical trial NCT07456696 about?

NCT07456696 is a clinical study titled "An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)". This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter...

What is the current status of trial NCT07456696?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-03. Estimated completion is 2027-12.

What conditions does trial NCT07456696 study?

This clinical trial studies the following conditions: Post Traumatic Stress Disorder.

What interventions are being tested in trial NCT07456696?

The interventions under investigation include: Placebo (DRUG), TSND-201 (DRUG).

Who is sponsoring clinical trial NCT07456696?

This trial is sponsored by Transcend Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07456696 being conducted?

This trial has 3 study locations across Arkansas, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post Traumatic Stress Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.